Heightened compliance risks require bespoke approach
This article was originally published in Clinica
Executive Summary
Pharma and medtech companies must put in place bespoke systems if they are to address the significant regulatory, financial and reputational risks they face for non-compliance as countries clamp down on bribery and corruption. Michael Boag and Ian Barclay examine the issues